MyFinsight
Home
Blog
About
Total revenue
$131,948K
(-23.00%↓ Y/Y)
Gain on sale of lab
products business
$112,966K
Interest income, net
$1,735K
(-66.29%↓ Y/Y)
Proceeds from sale of lab
products business, net
$164,792K
Sales of marketable
securities
$114,636K
Maturities of marketable
securities
$59,744K
Net income (loss)
$110,636K
(684.73%↑ Y/Y)
Accrued compensation
$17,189K
(189.05%↑ Y/Y)
Stock-based compensation
$10,654K
(-41.96%↓ Y/Y)
Depreciation and
amortization
$2,811K
(-61.61%↓ Y/Y)
Inventory
-$2,272K
(-133.70%↓ Y/Y)
Accounts receivable
-$2,040K
(-187.33%↓ Y/Y)
Amortization of right-of-use
assets
$1,237K
(-53.69%↓ Y/Y)
Accounts payable
$1,197K
(-26.34%↓ Y/Y)
Accrued and other
liabilities
$846K
(-84.74%↓ Y/Y)
Amortization of premium and
accretion of discount on...
-$502K
(10.68%↑ Y/Y)
Loss on disposal of
asset
-$210K
Other
-$51K
(-828.57%↓ Y/Y)
Deferred revenue
$1K
(-99.91%↓ Y/Y)
Canceled cashflow
$136,013K
Net cash provided by
investing activities
$280,586K
(1034.96%↑ Y/Y)
Net cash provided by
(used in) operating...
$30,604K
(283.38%↑ Y/Y)
Canceled cashflow
$58,586K
Canceled cashflow
$119,865K
Personnel cost
$49,033K
(-18.38%↓ Y/Y)
Other segment items
$18,991K
(-4.90%↓ Y/Y)
Cost of test
services, product, and...
$15,516K
(-46.74%↓ Y/Y)
Cost of test
services, product, and...
$14,447K
(-5.41%↓ Y/Y)
Business development and
portfolio optimization...
$11,078K
Stock-based compensation
expense
$10,615K
(-42.17%↓ Y/Y)
Professional and legal fees
$5,861K
(-74.00%↓ Y/Y)
Cost of test
services, product, and...
$4,327K
(-53.84%↓ Y/Y)
Research materials and
clinical trials expense
$4,088K
(-43.47%↓ Y/Y)
Depreciation and
amortization expense
$2,057K
(-65.14%↓ Y/Y)
Net increase
(decrease) in cash, cash...
$295,683K
(735.73%↑ Y/Y)
Canceled cashflow
$15,507K
something is missing
-$54,728K
Purchase of long term
investment
$2,000K
Additions of property and
equipment
$1,858K
Gain on sale of lab
products business
$112,966K
Prepaid and other assets
$5,495K
(31.77%↑ Y/Y)
Operating leases
liabilities, net
-$1,404K
(52.46%↑ Y/Y)
Proceeds from issuance of
common stock under...
$1,506K
(-33.71%↓ Y/Y)
Proceeds from exercise of
stock options
$1,245K
(-69.47%↓ Y/Y)
Net cash used in
financing activities
-$15,498K
(71.54%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$9K
(90.00%↑ Y/Y)
Canceled cashflow
$2,751K
Repurchase and retirement
of common stock
$12,232K
(-75.54%↓ Y/Y)
Taxes paid related to
net share...
$6,017K
(-35.33%↓ Y/Y)
Back
Back
Cash Flow
CareDx, Inc. (CDNA)
CareDx, Inc. (CDNA)
source: myfinsight.com